Correction to: Cancer Chemotherapy and Pharmacology (2019) 83:1175–1181 https://doi.org/10.1007/s00280-019-03820-7
The article “Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial”, written by Fernando Rivera, C. Romero, P. Jimenez–Fonseca, M. Izquierdo–Manuel, A. Salud, E. Martínez, M. Jorge, V. Arrazubi, J. C. Méndez, P. Garcia–Alfonso, M. Reboredo, J. Barriuso, N. Munoz–Unceta, R. Jimeno, C. López was originally published electronically on the publisher’s internet portal (currently SpringerLink) on 29th March 2019 without open access.
With the author(s)’ decision to opt for Open Choice the copyright of the article changed on 5th April 2019 to © The Author(s) 2019 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Additional information
The original version of this article was revised due to a retrospective Open Access order.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.
About this article
Cite this article
Rivera, F., Romero, C., Jimenez-Fonseca, P. et al. Correction to: Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial. Cancer Chemother Pharmacol 84, 1365 (2019). https://doi.org/10.1007/s00280-019-03964-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-019-03964-6